Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 8, 2011, Pages 1003-1021

  Hendriks, Rudi W ^a   Bredius, Robbert Gm ^b   Pike Overzet, Karin ^b   Staal, Frank Jt ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

B lymphocyte; Gene therapy; PID; Stem cell; X linked A gamma globulinemia

Indexed keywords

ATM PROTEIN; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; IMMUNOGLOBULIN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; B LYMPHOCYTE; CELL CYCLE ARREST; CELL MATURATION; CLINICAL FEATURE; DRUG COST; EXPRESSION VECTOR; GENE VECTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LONG TERMINAL REPEAT; NONHUMAN; NONVIRAL GENE THERAPY; PRE B LYMPHOCYTE; PROMOTER REGION; PROTEIN STRUCTURE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; STEM CELL GENE THERAPY; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X LINKED AGAMMAGLOBULINEMIA;

AGAMMAGLOBULINEMIA; ANIMALS; GENETIC DISEASES, INBORN; GENETIC DISEASES, X-LINKED; HUMANS; MICE; SIGNAL TRANSDUCTION;

EID: 79960257240     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.585971     Document Type: Article

References (154)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72 (Pubitemid 30241569)
2. Fischer A. Human primary immunodeficiency diseases: a perspective. Nat Immunol 2004;5:23-30 (Pubitemid 38081465)
3. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005;105:4255-7 (Pubitemid 40720770)
4. Aoki Y, Isselbacher KJ, Cherayil BJ, Pillai S. Tyrosine phosphorylation of Blk and Fyn Src homology 2 domain-binding proteins occurs in response to antigen-receptor ligation in B cells and constitutively in pre-B cells. Proc Natl Acad Sci USA 1994;91:4204-8 (Pubitemid 24143401)
5. Conley ME, Parolini O, Rohrer J, Campana D. X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol Rev 1994;138:5-21 (Pubitemid 24147413)
6. Conley ME, Rohrer J, Rapalus L, et al. Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol Rev 2000;178:75-90 (Pubitemid 32095221)
7. de Weers M, Brouns GS, Hinshelwood S, et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 1994;269:23857-60 (Pubitemid 24300906)
8. de Weers M, Verschuren MC, Kraakman ME, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993;23:3109-14 (Pubitemid 23353756)
9. Hendriks RW, de Bruijn MF, Maas A, et al. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J 1996;15:4862-72 (Pubitemid 26315797)
10. Middendorp S, Dingjan GM, Hendriks RW. Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice. J Immunol 2002;168:2695-703 (Pubitemid 34211646)
11. Middendorp S, Dingjan GM, Maas A, et al. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol 2003;171:5988-96 (Pubitemid 37467217)
12. Middendorp S, Zijlstra AJ, Kersseboom R, et al. Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood 2005;105:259-65 (Pubitemid 40053091)
13. Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-90 (Pubitemid 23044942)
14. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-33 (Pubitemid 23034471)
15. Felices M, Falk M, Kosaka Y, Berg LJ. Tec kinases in T cell and mast cell signaling. Adv Immunol 2007;93:145-84 (Pubitemid 46441430)
16. Andreotti AH, Bunnell SC, Feng S, et al. Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature 1997;385:93-7 (Pubitemid 27024562)
17. Thomas JD, Sideras P, Smith CI, et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993;261:355-8 (Pubitemid 23281006)
18. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358-61 (Pubitemid 23281007)
19. Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity 1995;3:283-99
20. Li T, Tsukada S, Satterthwaite A, et al. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 1995;2:451-60
21. Park H, Wahl MI, Afar DE, et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 1996;4:515-25 (Pubitemid 26354660)
22. Maas A, Dingjan GM, Grosveld F, Hendriks RW. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J Immunol 1999;162:6526-33 (Pubitemid 29309375)
23. Kersseboom R, Kil L, Flierman R, et al. Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells. Eur J Immunol 2010;40:2643-54
24. Melchers F, ten Boekel E, Seidl T et al. Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells. Immunol Rev 2000;175:33-46 (Pubitemid 30427154)
25. Hendriks RW, Middendorp S. The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol 2004;25:249-56 (Pubitemid 38501671)
26. Ohnishi K, Melchers F. The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling. Nat Immunol 2003;4:849-56 (Pubitemid 37098655)
27. Ubelhart R, Bach MP, Eschbach C, et al. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nat Immunol 2010;11:759-65
28. ten Boekel E, Yamagami T, Andersson J, et al. The formation and selection of cells expressing preB cell receptors and B cell receptors. Curr Top Microbiol Immunol 1999; 246: 3-9.
29. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-7 (Pubitemid 37075812)
30. Gauthier L, Rossi B, Roux F, et al. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc Natl Acad Sci USA 2002;99:13014-19
31. Bradl H, Wittmann J, Milius D, et al. Interaction of murine precursor B Cell receptor with stroma cells is controlled by the unique tail of lambda5 and stroma cell-associated heparan sulfate. J Immunol 2003;171:2338-48 (Pubitemid 37025540)
32. Kohler F, Hug E, Eschbach C, et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 2008;29:912-21
33. Keenan RA, De Riva A, Corleis B, et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 2008;321:696-9
34. Saito K, Scharenberg AM, Kinet JP. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5- trisphosphate directly regulates Btk. J Biol Chem 2001;276:16201-6
35. Mahajan S, Fargnoli J, Burkhardt AL, et al. Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mol Cell Biol 1995;15:5304-11
36. Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5 (Pubitemid 26058937)
37. Wahl MI, Fluckiger AC, Kato RM, et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Proc Natl Acad Sci USA 1997;94:11526-33 (Pubitemid 27451032)
38. Guo B, Kato RM, Garcia-Lloret M, et al. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 2000;13:243-53
39. Kouro T, Nagata K, Takaki S, et al. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol 2001;13:485-93 (Pubitemid 32475719)
40. Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell 2002;10:1057-69 (Pubitemid 36001972)
41. Tretter T, Ross AE, Dordai DI, Desiderio S. Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk. J Exp Med 2003;198:1863-73 (Pubitemid 38032119)
42. Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2002;2:354-63 (Pubitemid 37328758)
43. Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 2000;191:1745-54
44. Bajpai UD, Zhang K, Teutsch M, et al. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 2000;191:1735-44 (Pubitemid 30331570)
45. Schweighoffer E, Vanes L, Mathiot A, et al. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003;18:523-33 (Pubitemid 36513634)
46. Su Y, Jumaa H. LAT links the pre-BCR to calcium signaling. Immunity 2003;19:295-305 (Pubitemid 37011343)
47. Ellmeier W, Jung S, Sunshine MJ, et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med 2000;192:1611-24
48. Wen R, Chen Y, Schuman J, et al. An important role of phospholipase Cgamma1 in pre-B-cell development and allelic exclusion. EMBO J 2004;23:4007-17 (Pubitemid 39472422)
49. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 2004;22:563-98 (Pubitemid 38680434)
50. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 2009;9:195-205
51. Lindvall J, Islam TC. Interaction of Btk and Akt in B cell signaling. Biochem Biophys Res Commun 2002;293:1319-26 (Pubitemid 34681020)
52. Flemming A, Brummer T, Reth M, Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol 2003;4:38-43 (Pubitemid 36104706)
53. Jumaa H, Hendriks RW, Reth M. B cell signaling and tumorigenesis. Annu Rev Immunol 2005;23:415-45 (Pubitemid 40563176)
54. Malin S, McManus S, Cobaleda C, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2010;11:171-9
55. Nisitani S, Satterthwaite AB, Akashi K, et al. Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000;97:2737-42 (Pubitemid 30159241)
56. Belver L, de Yebenes VG, Ramiro AR. MicroRNAs prevent the generation of autoreactive antibodies. Immunity 2010;33:713-22
57. Bolland S, Pearse RN, Kurosaki T, Ravetch JV. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 1998;8:509-16 (Pubitemid 28196804)
58. Saito K, Tolias KF, Saci A, et al. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity 2003;19:669-78 (Pubitemid 37490792)
59. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006;176:3635-41 (Pubitemid 43364011)
60. Mukhopadhyay S, George A, Bal V, et al. Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol 1999;163:1786-92 (Pubitemid 29382176)
61. Liu X, Zhan Z, Li D, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12:416-24
62. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994;152:557-65 (Pubitemid 24072959)
63. Pearl ER, Vogler LB, Okos AJ, et al. B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol 1978;120:1169-75 (Pubitemid 8343816)
64. Landreth KS, Engelhard D, Anasetti C, et al. Pre-B cells in agammaglobulinemia: evidence for disease heterogeneity among affected boys. J Clin Immunol 1985;5:84-9 (Pubitemid 15124524)
65. Campana D, Farrant J, Inamdar N, et al. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol 1990;145:1675-80 (Pubitemid 20336728)
66. Nomura K, Kanegane H, Karasuyama H, et al. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway. Blood 2000;96:610-17 (Pubitemid 30463382)
67. Minegishi Y, Conley ME. Negative selection at the pre-BCR checkpoint elicited by human mu heavy chains with unusual CDR3 regions. Immunity 2001;14:631-41 (Pubitemid 32520873)
68. Minegishi Y, Rohrer J, Conley ME. Recent progress in the diagnosis and treatment of patients with defects in early B-cell development. Curr Opin Pediatr 1999;11:528-32
69. Conley ME. B cells in patients with X-linked agammaglobulinemia. J Immunol 1985;134:3070-4 (Pubitemid 16238272)
70. Conley ME, Puck JM. Carrier detection in typical and atypical X-linked agammaglobulinemia. J Pediatr 1988;112:688-94
71. Conley ME, Brown P, Pickard AR, et al. Expression of the gene defect in X-linked agammaglobulinemia. N Engl J Med 1986;315:564-7
72. Ng YS, Wardemann H, Chelnis J, et al. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med 2004;200:927-34 (Pubitemid 39362928)
73. Scher I, Ahmed A, Strong DM, et al. X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med 1975;141:788-803
74. Wicker LS, Scher I. X-linked immune deficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol 1986;124:87-101
75. Hardy RR, Hayakawa K, Parks DR, Herzenberg LA. Demonstration of B-cell maturation in X-linked immunodeficient mice by simultaneous three-colour immunofluorescence. Nature 1983;306:270-2 (Pubitemid 14232357)
76. Allman D, Lindsley RC, DeMuth W, et al. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001;167:6834-40 (Pubitemid 33144175)
77. Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002;168:2101-10 (Pubitemid 34171808)
78. Nahm MH, Paslay JW, Davie JM. Unbalanced X chromosome mosaicism in B cells of mice with X-linked immunodeficiency. J Exp Med 1983;158:920-31 (Pubitemid 13051354)
79. Forrester LM, Ansell JD, Micklem HS. Development of B lymphocytes in mice heterozygous for the X-linked immunodeficiency (xid) mutation. xid inhibits development of all splenic and lymph node B cells at a stage subsequent to their initial formation in bone marrow. J Exp Med 1987;165:949-58 (Pubitemid 17064497)
80. Martin F, Kearney JF. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity 2000;12:39-49 (Pubitemid 30069213)
81. Wicker LS, Guelde G, Scher I, Kenny JJ. The asymmetry in idiotype-isotype expression in the response to phosphocholine is due to divergence in the expressed repertoires of Lyb- 5+ and Lyb-5- B cells. J Immunol 1983;131:2468-76 (Pubitemid 14230082)
82. Anderson JS, Teutsch M, Dong Z, Wortis HH. An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci USA 1996;93:10966-71. [published erratum appears in Proc Natl Acad Sci USA 1996;93:15522]
83. Brorson K, Brunswick M, Ezhevsky S, et al. xid affects events leading to B cell cycle entry. J Immunol 1997;159:135-43 (Pubitemid 127493694)
84. Solvason N, Wu WW, Kabra N, et al. Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells. J Exp Med 1998;187:1081-91 (Pubitemid 28176408)
85. Reid GK, Osmond DG. B lymphocyte production in the bone marrow of mice with X-linked immunodeficiency (xid). J Immunol 1985;135:2299-302 (Pubitemid 16217111)
86. Dingjan GM, Middendorp S, Dahlenborg K, et al. Bruton's tyrosine kinase regulates the activation of gene rearrangements at the lambda light chain locus in precursor B cells in the mouse. J Exp Med 2001;193:1169-78 (Pubitemid 32488369)
87. Jumaa H, Mitterer M, Reth M, Nielsen PJ. The absence of SLP65 and Btk blocks B cell development at the preB cell receptor-positive stage. Eur J Immunol 2001;31:2164-9 (Pubitemid 32640733)
88. Kersseboom R, Middendorp S, Dingjan GM, et al. Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med 2003;198:91-8 (Pubitemid 36870189)
89. Hayashi K, Yamamoto M, Nojima T, et al. Distinct signaling requirements for Dmu selection, IgH allelic exclusion, pre-B cell transition, and tumor suppression in B cell progenitors. Immunity 2003;18:825-36 (Pubitemid 36780951)
90. Nakayama J, Yamamoto M, Hayashi K, et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 2009;113:1483-92
91. van Loo PF, Dingjan GM, Maas A, Hendriks RW. Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity 2007;27:468-80 (Pubitemid 47418671)
92. Kersseboom R, Ta VB, Zijlstra AJ, et al. Bruton's tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement. J Immunol 2006;176:4543-52
93. Schlissel MS, Stanhope-Baker P. Accessibility and the developmental regulation of V(D)J recombination. Semin Immunol 1997;9:161-70
94. Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002;141:566-71 (Pubitemid 35193325)
95. Conley ME, Rohrer J. The spectrum of mutations in Btk that cause X-linked agammaglobulinemia. Clin Immunol Immunopathol 1995;76:S192-7
96. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193-202 (Pubitemid 44107177)
97. Chun JK, Lee TJ, Song JW, et al. Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med J 2008;49:28-36 (Pubitemid 351513642)
98. Fiorini M, Franceschini R, Soresina A, et al. BTK: 22 novel and 25 recurrent mutations in European patients with X-linked agammaglobulinemia. Hum Mutat 2004;23(3):286
99. Wang Y, Kanegane H, Wang X, et al. Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China. J Clin Immunol 2009;29:352-6
100. Bayrakci B, Ersoy F, Sanal O, et al. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 2005;47:239-46 (Pubitemid 41535820)
101. Kanegane H, Nomura K, Futatani T, Miyawaki T. Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia. Nihon Rinsho Meneki Gakkai Kaishi 2002;25:337-43
102. Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221-30 (Pubitemid 35191097)
103. Baum C, von Kalle C, Staal FJ, et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004;9:5-13 (Pubitemid 38208322)
104. Brenner S, Malech HL. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim Biophys Acta 2003;1640:1-24 (Pubitemid 36369633)
105. Medin JA, Fowler DH. Post-transduction events in retrovirus-mediated gene therapy involving hematopoietic stem cells: beyond efficiency issues. J Cell Biochem Suppl 2002;38:46-54
106. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy-what have we learned? J Neurooncol 2003;65:227-36 (Pubitemid 37526815)
107. Strauss BE, Costanzi-Strauss E. Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency. Braz J Med Biol Res 2007;40:601-13 (Pubitemid 46711704)
108. Todd S, Anderson C, Jolly DJ, Craik CS. HIV protease as a target for retrovirus vector-mediated gene therapy. Biochim Biophys Acta 2000;1477:168-88 (Pubitemid 30119900)
109. Weber E, Anderson WF, Kasahara N. Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Curr Opin Mol Ther 2001;3:439-53 (Pubitemid 32998996)
110. Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007;117:2225-32 (Pubitemid 47219567)
111. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-42
112. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-19 (Pubitemid 37296260)
113. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008;8:419-29
114. Vanden Driessche T, Chuah MK. Moving gene therapy forward with mobile DNA. Hum Gene Ther 2009;20:1559-61
115. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000;302:93-102
116. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41 (Pubitemid 30257033)
117. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-7 (Pubitemid 40018447)
118. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-58
119. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009;682-9
120. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9
121. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Eng J Med 2010;363:1918-27
122. Pike-Overzet K, de Ridder D, Weerkamp F, et al. Gene therapy: is IL2RG oncogenic in T-cell development? Nature 2006;443:E5; discussion E6-E7. (Pubitemid 44435139)
123. Pike-Overzet K, de Ridder D, Weerkamp F, et al. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007;21:754-63 (Pubitemid 46444560)
124. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7 (Pubitemid 26119138)
125. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72:9873-80 (Pubitemid 28520853)
126. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-22
127. Pike-Overzet K, Rodijk M, Ng YY, et al. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 2011; In press
128. Yu PW, Tabuchi RS, Kato RM, et al. Sustained correction of B cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood 2004;104:1281-90 (Pubitemid 39166501)
129. Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia 2008;22:1849-52
130. Kerns HM, Ryu BY, Stirling BV, et al. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 2010;115:2146-55
131. Moreau T, Barlogis V, Bardin F, et al. Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA. Gene Ther 2008;15:942-52 (Pubitemid 351791481)
132. Ng YY, Baert MR, Pike-Overzet K, et al. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia 2010;24:1617-30
133. Scher I, Steinberg AD, Berning AK, Paul WE. X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med 1975;142:637-50
134. Bence K, Ma W, Kozasa T, Huang XY. Direct stimulation of Bruton's tyrosine kinase by Gq-protein alpha-subunit. Nature 1997;389:296-9 (Pubitemid 27406645)
135. Pike-Overzet K, van der Burg M, Wagemaker G, et al. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007;15:1910-16 (Pubitemid 350011729)
136. Herman SE, Gordon AL, Hertlein E, et al. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011: Published online 21 March 2011, doi: 10.1182/blood-2011-01-328484
137. Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre- B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci USA 1994;91:10606-9 (Pubitemid 24329047)
138. Saouaf SJ, Mahajan S, Rowley RB, et al. Temporal differences in the activation of three classes of non- transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci USA 1994;91:9524-8
139. de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007;26:93-104 (Pubitemid 46109347)
140. Santos-Argumedo L, Lund FE, Heath AW, et al. CD38 unresponsiveness of xid B cells implicates Bruton's tyrosine kinase (btk) as a regular of CD38 induced signal transduction. Int Immunol 1995;7:163-70
141. Schmidt U, Van Den Akker E, Parren-Van Amelsvoort M, et al. Btk Is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med 2004;199:785-95 (Pubitemid 38375198)
142. Kawakami Y, Yao L, Miura T, et al. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon FcepsilonRI cross-linking. Mol Cell Biol 1994;14:5108-13 (Pubitemid 24235938)
143. Launay P, Lehuen A, Kawakami T, et al. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol 1998;63:636-42 (Pubitemid 28193778)
144. Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 2008;181:288-98
145. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998;8:1137-40 (Pubitemid 28501379)
146. Sato S, Katagiri T, Takaki S, et al. IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J Exp Med 1994;180:2101-11 (Pubitemid 24351591)
147. Matsuda T, Takahashi-Tezuka M, Fukada T, et al. Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood 1995;85:627-33
148. Jefferies CA, Doyle S, Brunner C, et al. Bruton's tyrosine kinase is a Toll/ interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor. J Biol Chem 2003;278:26258-64 (Pubitemid 36835395)
149. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem 2007;282:36953-60
150. Taneichi H, Kanegane H, Sira MM, et al. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol 2008;126:148-54
151. Halcomb KE, Musuka S, Gutierrez T, et al. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol 2008;46:233-41
152. Tsukamoto Y, Nagai Y, Kariyone A, et al. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production. Mol Immunol 2009;46:1278-88
153. Lee KG, Xu S, Wong ET, et al. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL- 12 production in TLR9-stimulated B Cells. J Biol Chem 2008;283:11189-98
154. Rock J, Schneider E, Grun JR, et al. CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2. Eur J Immunol 2007;37:3564-75